AMG-386

Other Medications

Description

AMG 386 is an investigational medication being studied by Amgen for colorectal cancer. It is currently in Phase 2 clinical trials. One study (NCT00752570) is evaluating AMG 386 in combination with FOLFIRI (a standard chemotherapy regimen containing 5-Fluorouracil, Irinotecan, and Leucovorin) compared to FOLFIRI alone. This trial is specifically for patients with metastatic colorectal cancer who have previously received treatment. The goal is to see if adding AMG 386 to FOLFIRI improves outcomes compared to FOLFIRI alone in this setting. AMG 386 is not yet approved for use in colorectal cancer or any other condition.

Mechanism of Action

The specific way AMG 386 works (its mechanism of action) is not fully detailed in the available trial information. It is being studied in combination with FOLFIRI, a standard chemotherapy regimen, suggesting it may work by a different pathway or enhance the effects of chemotherapy. Further research is needed to understand its precise molecular target or mechanism.

Side Effects

As AMG 386 is an investigational drug in Phase 2 trials Comprehensive safety data is still being collected. The side effects observed in the NCT00752570 trial will be compared between the AMG 386 + FOLFIRI group and the FOLFIRI alone group. Specific side effects associated with AMG 386 itself are still being evaluated in ongoing clinical trials.

Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.

Clinical Trials

NCT00752570 Phase 2
Archived
A Phase 2, Randomized, Double Blind, Placebo Controlled Study of AMG 386 in Combination With FOLFIRI in Subjects With Previously Treated Metastatic Colorectal Carcinoma